Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

195.92
-8.9400-4.36%
Post-market: 196.500.5800+0.30%19:59 EDT
Volume:3.04M
Turnover:600.18M
Market Cap:41.99B
PE:-21.96
High:205.15
Open:204.84
Low:193.58
Close:204.86
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:2.55
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.11
PE(LYR):-32.93

Loading ...

J.P. Morgan Sticks to Their Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
Sep 02

Revolution Medicines Signs Long-Term Headquarters Lease Agreement

TIPRANKS
·
Sep 01

Revolution Medicines (RVMD) Could Be 7% Below Fair Value On FDA Approval Of RASONQUE

Simply Wall St.
·
Sep 01

Revolution Medicines is Maintained at Buy by Needham

Dow Jones
·
Aug 31

Ami Fadia Raises RVMD Price Target to $275 on Strong Rasonque U.S. Launch Economics and Robust Oncology Pipeline

TIPRANKS
·
Aug 31

Revolution Medicines, Inc. : Needham Raises Target Price to $275 from $240

THOMSON REUTERS
·
Aug 31

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

Reuters
·
Aug 31

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live
·
Aug 29

Movement Alert|Revolution Medicines, Inc. Falls 5.02% in Regular Trading, Profit-Taking Follows FDA Approval of Pancreatic Cancer Drug

Market Focus
·
Aug 28

UBS Adjusts Revolution Medicines Price Target to $265 From $220, Maintains Buy Rating

MT Newswires Live
·
Aug 28

Revolution Medicines is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 28

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Deep News
·
Aug 28

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Dow Jones
·
Aug 28

Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live
·
Aug 28

Revolution Medicines Stock (RVMD) Gets Price Target Hike on New Revenue-Generating Cancer Drug

TIPRANKS
·
Aug 28

Revolution Medicines is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Aug 27

Revolution Medicines price target raised to $320 from $230 at Evercore ISI

TIPRANKS
·
Aug 27

Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era

Reuters
·
Aug 27